These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 1756252

  • 1. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H, Yoshioka A, Shima M, Tanaka I, Koshihara K, Fukutake K, Fujimaki M.
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [Abstract] [Full Text] [Related]

  • 2. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U, Luboshitz J, Bashari D, Ravid B, Gorina E, Regan L, Stass H, Lubetsky A.
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [Abstract] [Full Text] [Related]

  • 3. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
    White GC, Courter S, Bray GL, Lee M, Gomperts ED.
    Thromb Haemost; 1997 Apr; 77(4):660-7. PubMed ID: 9134639
    [Abstract] [Full Text] [Related]

  • 4. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
    Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ.
    N Engl J Med; 1990 Dec 27; 323(26):1800-5. PubMed ID: 2123300
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
    Shirahata A, Fukutake K, Takamatsu J, Shima M, Yoshioka A.
    Int J Hematol; 2000 Jul 27; 72(1):101-7. PubMed ID: 10979218
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM, Rokicka-Milewska R, Lopaciuk S, Skotnicki AB, Klukowska A, Laguna P, Windyga J, Kotitschke R, Struff WG.
    Haemophilia; 2004 Sep 27; 10(5):438-48. PubMed ID: 15357768
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C, Dunkerley A, Sørensen B, Rangarajan S.
    Haemophilia; 2009 Nov 27; 15(6):1237-42. PubMed ID: 19664015
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes.
    Dayan I, Robinson M, Baru M.
    Haemophilia; 2009 Sep 27; 15(5):1006-13. PubMed ID: 19486171
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S, Dasgupta S, André S, Navarrete AM, Kaveri SV, Bayry J, André MH, Chtourou S, Tellier Z, Lacroix-Desmazes S.
    Haematologica; 2007 Oct 27; 92(10):1423-6. PubMed ID: 18024377
    [Abstract] [Full Text] [Related]

  • 10. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
    Singer ST, Addiego JE, Reason DC, Lucas AH.
    Thromb Haemost; 1996 Jul 27; 76(1):17-22. PubMed ID: 8819245
    [Abstract] [Full Text] [Related]

  • 11. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
    Martinowitz U, Bjerre J, Brand B, Klamroth R, Misgav M, Morfini M, Santagostino E, Tiede A, Viuff D.
    Haemophilia; 2011 Nov 27; 17(6):854-9. PubMed ID: 21443634
    [Abstract] [Full Text] [Related]

  • 12. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM.
    Haematologica; 2000 Oct 27; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [Abstract] [Full Text] [Related]

  • 13. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K, Berntorp E, ten Cate JW, Johnsson H, Peters M, Savidge G, Tengborn L, Spira J, Stahl C.
    Thromb Haemost; 1997 Feb 27; 77(2):298-302. PubMed ID: 9157585
    [Abstract] [Full Text] [Related]

  • 14. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A.
    Ther Drug Monit; 2012 Feb 27; 34(1):110-7. PubMed ID: 22249347
    [Abstract] [Full Text] [Related]

  • 15. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
    Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E.
    Thromb Haemost; 2000 Jun 27; 83(6):811-6. PubMed ID: 10896230
    [Abstract] [Full Text] [Related]

  • 16. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
    Powell JS, Nugent DJ, Harrison JA, Soni A, Luk A, Stass H, Gorina E.
    J Thromb Haemost; 2008 Feb 27; 6(2):277-83. PubMed ID: 18039351
    [Abstract] [Full Text] [Related]

  • 17. Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A.
    Kelly KM, Butler RB, Farace L, Cohen AR, Manno CS.
    J Pediatr; 1997 Apr 27; 130(4):537-40. PubMed ID: 9108849
    [Abstract] [Full Text] [Related]

  • 18. Recombinant factor VIII concentrates.
    Franchini M, Lippi G.
    Semin Thromb Hemost; 2010 Jul 27; 36(5):493-7. PubMed ID: 20632247
    [Abstract] [Full Text] [Related]

  • 19. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E, Smith J, Kavanagh M, Nolan B, White B.
    Thromb Haemost; 2007 Dec 27; 98(6):1188-92. PubMed ID: 18064312
    [Abstract] [Full Text] [Related]

  • 20. The first recombinant FVIII produced in human cells--an update on its clinical development programme.
    Valentino LA, Negrier C, Kohla G, Tiede A, Liesner R, Hart D, Knaub S.
    Haemophilia; 2014 Jan 27; 20 Suppl 1():1-9. PubMed ID: 24330348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.